About Us

Jeffrey K. Allen, PhD

President and Founder, Tumorgen MDx

Jeff Allen has a strong technical background with R&D training as an Analytical Biochemist combined with over 20 years of biotechnology marketing experience. Throughout his career, Jeff has utilized both technical and business skill sets in identifying, creating and launching molecular based products that address significant clinical needs.

Connect with LinkedIn

Alexander G. Allen

Senior Research Scientist, TumorGen MDx

Alex is pursuing a doctorate degree in microbiology / virology at Drexel University College of Medicine where his research focus is on viral pathogenic genes. In addition to his research, Alex is also supporting development of our CSC3™ device, particularly on maintaining cell cluster viability.



Connect with LinkedIn

Austin E. Allen

Senior Engineering Scientist, TumorGen MDx

Austin is studying for a bachelor’s degree in industrial technology at San Jose State Univ. with an interest in microfluidic systems. His experience with AutoCAD® software was essential in the design of our CSC3™ device and he identified 3D Printing as our best method to manufacture microfluidic chips




Connect with LinkedIn

Scientific Advisory Board

Mihee M. Kim, PhD

A molecular and cellular biologist with research experience in studying transcription factors related to self-renewal within stem cells.
Connect with LinkedIn

Bart Wanders, PhD

Senior Executive within Research and Development for bioresearch/biotechnology detection systems
Connect with LinkedIn

Peter Teriete, PhD

A Research Scientist at Sanford Burnham Prebys Medical Discovery Institute with research experience in identifying biomarkers unique to tumorigenic cells.
Connect with LinkedIn

Yadwinder Deol, PhD

A Post-Doctoral Research Fellow within the Wicha Lab at the University of Michigan, working on breast cancer stem cell proteomics related to tumor initiation.
Connect with LinkedIn

Nicholas Cosford, PhD

A Professor and Associate Director of Translational Research at Sanford Burnham Prebys Medical Discovery Institute with active research programs developing small-molecule cancer therapeutics.
Connect with LinkedIn

Business Development

Current corporation status

TumorGen MDx, is a Limited Liability Corporation (LLC) filed in the state of California as of 31st of January, 2012 and is currently active in the area of biotechnology.

Seeking Supporters

TumorGen MDx is actively seeking financial support for the development and adoption of a platform capable of isolating and capturing cancer stem cells.

Careers

TumorGen MDx is a newly formed corporation which is currently seeking scientific collaborators. In the future we will be looking for experienced Molecular Biologists w/ CSC capture and single cell WGS experience.

Seeking collaborations

TumorGen MDx is open to research collaborations with the National Comprehensive Cancer Centers

Contact Us

Drop us a line at info@TumorGenMDx.com

Disclaimer

The information provided within this website represents opinions and experiences which may not be in agreement with the original authors, their organizations or companies which have provided the original materials. The content is intended to be educational and any information provided should not be considered as medical advice, a clinical diagnostic result or a recommendation for specific treatment. Please consult with your personal physician prior to beginning any type of medical care related to a cancer diagnosis or other illness. Information contained within this website and the corresponding links are in some cases considered ‘forward looking statements’ and therefore may not be the current medical best practice. Never disregard, delay or avoid obtaining medical treatment or guidance from a licensed physician as a result of the information contained within this website. Some of the medical procedures, targeted therapies or diagnostic analyses may not be approved by regulatory agencies including the U.S. Food and Drug Administration. No guarantees or assurances of medical outcomes can be assumed based on the information within this website.